Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.

Levy A, Hendriks LEL, Berghmans T, Faivre-Finn C, GiajLevra M, GiajLevra N, Hasan B, Pochesci A, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Besse B, Novello S, Dingemans AC; EORTC Lung Cancer Group (EORTC LCG).

Eur J Cancer. 2019 Nov;122:109-114. doi: 10.1016/j.ejca.2019.09.012. Epub 2019 Oct 28.

PMID:
31671363
2.

Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.

Hendriks LEL, Dooms C, Berghmans T, Novello S, Levy A, De Ruysscher D, Hasan B, Giaj Levra M, Giaj Levra N, Besse B, Vansteenkiste J, Dingemans AC; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group.

Eur J Cancer. 2019 Oct 23;123:28-35. doi: 10.1016/j.ejca.2019.09.013. [Epub ahead of print]

PMID:
31655358
3.

[Lung transplantation for lepidic invasive adenocarcinoma: From a clinical question to an ethical consideration].

Créquit P, Cadranel J, Mal H, Grigoriu B, Berghmans T.

Rev Mal Respir. 2019 Oct;36(8):919-923. doi: 10.1016/j.rmr.2019.07.003. Epub 2019 Sep 11. French. No abstract available.

PMID:
31521430
4.

Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey.

Levy A, Hendriks LEL, Le Péchoux C, Falk S, Besse B, Novello S, Dingemans AC, Hasan B, Reck M, Berghmans T, Faivre-Finn C; EORTC Lung Cancer Group (EORTC LCG).

Lung Cancer. 2019 Oct;136:145-147. doi: 10.1016/j.lungcan.2019.08.007. Epub 2019 Aug 13.

PMID:
31520867
5.

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.

Dingemans AC, Hendriks LEL, Berghmans T, Levy A, Hasan B, Faivre-Finn C, Giaj-Levra M, Giaj-Levra N, Girard N, Greillier L, Lantuéjoul S, Edwards J, O'Brien M, Reck M, Smit EF, Van Schil P, Postmus PE, Ramella S, Lievens Y, Gaga M, Peled N, Scagliotti GV, Senan S, Paz-Ares L, Guckenberger M, McDonald F, Ekman S, Cufer T, Gietema H, Infante M, Dziadziuszko R, Peters S, Porta RR, Vansteenkiste J, Dooms C, de Ruysscher D, Besse B, Novello S.

J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655-0. doi: 10.1016/j.jtho.2019.07.025. [Epub ahead of print]

PMID:
31398540
6.

Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review.

Giaj-Levra N, Giaj-Levra M, Durieux V, Novello S, Besse B, Hasan B, Hendriks LE, Levy A, Dingemans AC, Berghmans T; European Organization for Research and Treatment of Cancer-Lung Cancer Group.

J Thorac Oncol. 2019 Jun 11. pii: S1556-0864(19)30458-7. doi: 10.1016/j.jtho.2019.05.037. [Epub ahead of print] Review.

PMID:
31195177
7.

[Lung cancer: Prognosis in intensive care depends mainly on the acute complication].

Gorham J, Ameye L, Paesmans M, Berghmans T, Sculier JP, Meert AP.

Rev Mal Respir. 2019 Mar;36(3):333-341. doi: 10.1016/j.rmr.2018.05.014. Epub 2019 Mar 18. French.

PMID:
30898468
8.

The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses.

Rosière R, Berghmans T, De Vuyst P, Amighi K, Wauthoz N.

Cancers (Basel). 2019 Mar 7;11(3). pii: E329. doi: 10.3390/cancers11030329. Review.

9.

Systemic treatments for thymoma and thymic carcinoma: A systematic review.

Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP, Moretti L, Ocak S, Roelandts M, Girard N.

Lung Cancer. 2018 Dec;126:25-31. doi: 10.1016/j.lungcan.2018.10.018. Epub 2018 Oct 18. Review.

PMID:
30527189
10.

Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries.

Rich A, Baldwin D, Alfageme I, Beckett P, Berghmans T, Brincat S, Burghuber O, Corlateanu A, Cufer T, Damhuis R, Danila E, Domagala-Kulawik J, Elia S, Gaga M, Goksel T, Grigoriu B, Hillerdal G, Huber RM, Jakobsen E, Jonsson S, Jovanovic D, Kavcova E, Konsoulova A, Laisaar T, Makitaro R, Mehic B, Milroy R, Moldvay J, Morgan R, Nanushi M, Paesmans M, Putora PM, Samarzija M, Scherpereel A, Schlesser M, Sculier JP, Skrickova J, Sotto-Mayor R, Strand TE, Van Schil P, Blum TG.

BMC Cancer. 2018 Nov 20;18(1):1144. doi: 10.1186/s12885-018-5009-y.

11.

SMAD4 Mutation in Small Cell Transformation of Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma.

D'Haene N, Le Mercier M, Salmon I, Mekinda Z, Remmelink M, Berghmans T.

Oncologist. 2019 Jan;24(1):9-13. doi: 10.1634/theoncologist.2018-0016. Epub 2018 Nov 9.

PMID:
30413663
12.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
13.

L'éditorial du redacteur en chef.

Berghmans T.

Rev Med Brux. 2018;39(4):201. French. No abstract available.

PMID:
30320978
14.

Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry.

Süveg K, Putora PM, Berghmans T, Glatzer M, Kovac V, Cihoric N.

Lung Cancer. 2018 Oct;124:12-18. doi: 10.1016/j.lungcan.2018.07.007. Epub 2018 Jul 5. Review.

PMID:
30268449
15.

New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey.

Berghmans T, Evison M, Blum TG, Peled N, Cadranel J.

ERJ Open Res. 2018 Sep 3;4(3). pii: 00040-2018. doi: 10.1183/23120541.00040-2018. eCollection 2018 Jul.

16.

Le mot du Rédac-Chef.

Berghmans T.

Rev Med Brux. 2018;39(3):131. French. No abstract available.

PMID:
29964386
17.

Une nouvelle étoile au firmament scientifique.

Berghmans T.

Rev Med Brux. 2018;39(2):68. French. No abstract available.

PMID:
29722486
18.

[Evolution and revolution in systemic treatment of lung cancer. The new role of immunotherapy].

Duruisseaux M, Berghmans T.

Rev Mal Respir. 2018 Feb;35(2):101-102. doi: 10.1016/j.rmr.2018.02.006. French. No abstract available.

PMID:
29548518
19.

Revue Médicale de Bruxelles : nouveautés et changement pour 2018.

Berghmans T.

Rev Med Brux. 2018;39(1):3. French. No abstract available.

PMID:
29528591
20.

A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.

Sculier JP, Lafitte JJ, Berghmans T, Meert AP, Scherpereel A, Roelandts M, Van Cutsem O, Colinet B, Bonduelle Y, Giner V, Paesmans M, Leclercq N, Van Houtte P.

Lung Cancer. 2018 Mar;117:32-37. doi: 10.1016/j.lungcan.2017.12.016. Epub 2018 Jan 31.

PMID:
29496253
21.

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.

PMID:
29477100
22.

Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Costantini A, Grynovska M, Lucibello F, Moisés J, Pagès F, Tsao MS, Shepherd FA, Bouchaab H, Garassino M, Aerts JGJV, Mazières J, Mondini M, Berghmans T, Meert AP, Cadranel J.

Eur Respir J. 2018 Feb 14;51(2). pii: 1702072. doi: 10.1183/13993003.02072-2017. Print 2018 Feb.

23.

[Impact of routine brain imaging in the initial management of lung cancer].

Niviere P, Sculier JP, Meert AP, Berghmans T.

Rev Mal Respir. 2018 Jan;35(1):55-61. doi: 10.1016/j.rmr.2017.11.004. Epub 2018 Feb 4. French.

PMID:
29397303
24.

[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma].

Berghmans T, Grigoriu B, Sculier JP, Meert AP.

Rev Mal Respir. 2018 Feb;35(2):197-205. doi: 10.1016/j.rmr.2017.11.007. Epub 2018 Feb 1. Review. French.

PMID:
29395567
25.

Quelques réflexions sur partage et considération pour autrui.

Berghmans T.

Rev Med Brux. 2017;38(6):467. French. No abstract available.

PMID:
29318800
26.

Médecine et politique : une cohabitation difficile.

Berghmans T.

Rev Med Brux. 2017;38(5):403. French. No abstract available.

PMID:
29178687
27.

L'éditorial du redacteur en chef.

Berghmans T.

Rev Med Brux. 2017;38(4):201. French. No abstract available.

PMID:
28981219
28.

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer.

Berghmans T, Scherpereel A, Meert AP, Giner V, Lecomte J, Lafitte JJ, Leclercq N, Paesmans M, Sculier JP; European Lung Cancer Working Party (ELCWP).

Front Oncol. 2017 Sep 19;7:217. doi: 10.3389/fonc.2017.00217. eCollection 2017.

29.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.

Sculier C, Bentea G, Ruelle L, Grigoriu B, Coureau M, Gorham J, Sideris S, Holbrechts S, Lafitte JJ, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Sep;111:164-175. doi: 10.1016/j.lungcan.2017.07.026. Epub 2017 Jul 24. Review.

PMID:
28838389
30.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.

Ruelle L, Bentea G, Sideris S, El Koulali M, Holbrechts S, Lafitte JJ, Grigoriu B, Sculier C, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Sep;111:150-163. doi: 10.1016/j.lungcan.2017.07.025. Epub 2017 Jul 25. Review.

PMID:
28838388
31.

[Immunotherapy and non-small cell lung cancer : a (r)evolution].

Berghmans T, Meert AP.

Rev Med Brux. 2017;38(3):175-177. French.

PMID:
28653522
32.

Le mot du Rédac-Chef.

Berghmans T.

Rev Med Brux. 2017;38(3):131. French. No abstract available.

PMID:
28653510
33.

L’ouverture à l’autre et la tolérance, un pas obligé vers une société plus sûre.

Berghmans T.

Rev Med Brux. 2017;38(2):67. French. No abstract available.

PMID:
28525243
34.

Editorial.

Berghmans T.

Rev Med Brux. 2017;38(1):3. French. No abstract available.

PMID:
28525194
35.

Intensive care in thoracic oncology.

Meert AP, Grigoriu B, Licker M, Van Schil PE, Berghmans T.

Eur Respir J. 2017 May 11;49(5). pii: 1602189. doi: 10.1183/13993003.02189-2016. Print 2017 May. Review.

36.

The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.

Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, Reck M, Berghmans T, Wasag B, Besse B, Dziadziuszko R.

Clin Lung Cancer. 2017 Sep;18(5):583-588. doi: 10.1016/j.cllc.2017.02.005. Epub 2017 Mar 1.

37.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.

Holbrechts S, Gorham J, Sideris S, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Apr;106:93-101. doi: 10.1016/j.lungcan.2017.01.016. Epub 2017 Jan 30. Review.

PMID:
28285701
38.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 3: Neurological paraneoplastic syndromes, involving the central nervous system.

Bentea G, Sculier C, Grigoriu B, Meert AP, Durieux V, Berghmans T, Sculier JP.

Lung Cancer. 2017 Apr;106:83-92. doi: 10.1016/j.lungcan.2017.01.017. Epub 2017 Jan 30. Review.

PMID:
28285700
39.

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature.

Durieux V, Coureau M, Meert AP, Berghmans T, Sculier JP.

Lung Cancer. 2017 Apr;106:102-109. doi: 10.1016/j.lungcan.2017.01.015. Epub 2017 Jan 30. Review.

PMID:
28285683
40.

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.

Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF; EMPHASIS-lung Collaborative Group.

J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.

41.

Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors.

Levacq D, D'Haene N, de Wind R, Remmelink M, Berghmans T.

Lung Cancer. 2016 Dec;102:38-41. doi: 10.1016/j.lungcan.2016.10.012. Epub 2016 Oct 27.

PMID:
27987586
42.

Are Intensive Cares Worthwhile for Breast Cancer Patients: The Experience of an Oncological ICU.

Destrebecq V, Lieveke A, Berghmans T, Paesmans M, Sculier JP, Meert AP.

Front Med (Lausanne). 2016 Oct 31;3:50. eCollection 2016.

43.

VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study.

Berghmans T, Lafitte JJ, Scherpereel A, Ameye L, Paesmans M, Meert AP, Colinet B, Tulippe C, Willems L, Leclercq N, Sculier JP; European Lung Cancer Working Party.

ERJ Open Res. 2015 Oct 19;1(2). pii: 00029-2015. eCollection 2015 Oct.

44.

Continuous Renal Replacement Therapy for Acute Renal Failure in Patients with Cancer: A Well-Tolerated Adjunct Treatment.

Fischler R, Meert AP, Sculier JP, Berghmans T.

Front Med (Lausanne). 2016 Aug 3;3:33. doi: 10.3389/fmed.2016.00033. eCollection 2016.

45.

L'euthanasie et la gestion de fin de vie: un débat éthique permanent.

Berghmans T.

Rev Med Brux. 2016 Mar-Apr;37(2):69. French. No abstract available.

PMID:
27487690
46.

[The Glasgow inflammatory score and lung cancer: A predictor of admissions to emergency units].

Gorham J, Ameye L, Paesmans M, Berghmans T, Sculier JP, Meert AP.

Rev Mal Respir. 2016 Nov;33(9):759-765. doi: 10.1016/j.rmr.2016.02.004. Epub 2016 Mar 24. French.

PMID:
27017064
47.

[Difficulties and limitations in conducting translational research in thoracic oncology. A practical example].

Meert AP, Ameye L, Leclercq N, Paesmans M, Remmelink M, Sculier JP, Berghmans T.

Rev Mal Respir. 2016 Sep;33(7):594-9. doi: 10.1016/j.rmr.2015.10.744. Epub 2016 Jan 6. French.

PMID:
26777111
48.

Les études de médecine: un parcours du combattant ?

Berghmans T.

Rev Med Brux. 2016;37(5):395. French. No abstract available.

PMID:
28525206
49.

[Oncological intensive care: 2013 and 2014 years'review].

Sculier JP, Bucalau AM, Closset C, Compagnie M, Gorham J, Sideris S, De Roodebeek DT, Wang XX, Berghmans T, Meert AP.

Rev Med Brux. 2016;37(3):159-167. Review. French.

PMID:
28525189
50.

Le mot du Rédacteur en Chef.

Berghmans T.

Rev Med Brux. 2016;37(3):131. French. No abstract available.

PMID:
28525183

Supplemental Content

Loading ...
Support Center